Study Condition(s): Breast Cancer

A Study to Compare Treatment After Surgery of Abemaciclib (LY2835219) Combined With Standard Endocrine Therapy Versus Endocrine Therapy Alone in Participants With Breast Cancer (monarchE)

Study Alias: JPCF

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT03155997 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The purpose of this study is to test whether the combination of the study drug abemaciclib plus adjuvant endocrine therapy improves outcomes in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer compared to adjuvant endocrine therapy along.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18+ years

Time Commitment

Your study participation is expected to be approximately 10 years
  • Participant must have confirmed hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-) breast cancer
  • Participant must have received surgery for this breast cancer
  • Participant must start study treatment within 12 weeks of completing their last non-endocrine treatment
  • Female participant of child-bearing potential must have a negative serum pregnancy test and agree to use highly effective birth control methods
  • Female participant must not be pregnant or breastfeeding
  • Participant must be able to swallow oral medications
  • Participant must not have Stage IA or Stage IV disease
  • Participant must not have previously received treatment with any CDK4 and CDK6 inhibitor
  • Participant must not have received more than 8 weeks of endocrine therapy after surgery
  • Participant must not have received an experimental treatment in a clinical trial within the last 30 days

Where to Participate

537 locations are currently available of 550 planned
Invalid Postal Code.
Please re-enter postal code.
Alert Me Icon Sign up for email alerts about new Lilly trials and locations.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}
Alert Me Icon Sign up for email alerts about new Lilly trials and locations.

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.